NeRRe Therapeutics is a UK based clinical-stage company developing a unique pipeline of three neurokinin(NK)-1 antagonists for the treatment of common, chronic and debilitating conditions caused by neuronal hypersensitivity associated with neurokinin-1 receptor system dysfunction.
NeRRe Therapeutics’ portfolio is tackling a range of disorders with high unmet need including chronic refractory cough and chronic pruritus.
The lead compound orvepitant, a potent and highly selective NK-1 receptor antagonist, is in a Phase 2b multinational trial to assess its benefit in patients with chronic refractory cough. It has the potential to be a first-in-class once-daily oral therapy, bringing significant benefits to sufferers of this incapacitating condition for which there are currently no approved medicines.
Cough is the most common symptom that causes patients to seek medical advice in the USA. Data from the National Ambulatory Medical Care Survey 2010 indicates that there were over 30 million cough-related ambulatory care visits to US physicians over this time period. Cough disrupts patients’ lives with physical, social, and psychological effects. Although most patients seeking treatment have a transient cough associated with viral upper respiratory tract infections, up to 12% may have chronic cough, defined as a cough that lasts longer than 8 weeks. Despite the prevalence and disruptive nature of this chronic condition there remains no effective, safe, and well tolerated antitussive treatments for patients desperate for relief.
NeRRe Therapeutics is led by an experienced management team. The company is backed by international life sciences investors: Advent Life Sciences, Fountain Healthcare Partners, Forbion Capital Partners and OrbiMed, all of whom took part in a £23m Series B fundraising in 2017. The company was founded in 2012 as a spin out from GSK, which transferred its NK antagonist portfolio, including clinical data, toxicity, safety and formulation packages, and all associated intellectual property to NeRRe. The company has built on this package, generating exciting new preclinical and clinical data to support the progression of its portfolio and creating further value with novel intellectual property.
The unique neurokinin-1,3 receptor antagonist NT-814 was demerged from NeRRe Therapeutics as KaNDy Therapeutics in September 2017, in order to focus on its potential as an innovative medicine in Women’s Health.
NeRRe is based at the state-of-the-art Stevenage Bioscience Catalyst (www.stevenagecatalyst.com), the UK’s first open innovation bioscience campus.